| |
[摘要]：Multiple sclerosis (MS) is on inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to myelin and oxonol damage. Although first described in the 14th century, MS was untreatable until the 1990s, when interferon beta (IFN-beta) reached the market for the first time. Four different IFNs and glatiramer acetate all obtained regulatory approval in the 1990s, radically influencing the treatment of MS. Since then, novel strategies hove been developed for the treatment of MS, including targeting of leukocyte differentiation molecules, costimulatory molecules, antiadhesion molecules and chemotaxis; immunomodulatory agents, autologous stem cell transplantation, anti-infectious therapies and strategies for neuroprotection, neurorepair and remyelination hove also emerged. However, there is still no cure for MS and existing treatments serve only to slow disease progression and mitigate symptoms. The search for effective treatments for MS continues, with researchers focusing on the identification of novel targets for therapeutic intervention. This article presents those drug targets that ore currently under active investigation for the treatment of MS. |
|
